The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Abstract
The purpose of our study was to determine how ATP-Magnesium Chloride might be used, what the potential problems with ATP-MGCL2 might be and to develop all the necessary background information in order to initiate clinical trials. In normal as well as hypovelemic awake dogs, cardiac output can be increased significantly by infusion of ATP-MGL2 intravenously at rates of 0.5-2.5 mg/Kg/min. Although higher doses of S4ATP-MgL2 may have detrimental hemodynamic effects, such effects are immediately reversible by ceasing ATP-MgCL2 infusion. Moreover, the deleterious hemodynamic effects of very high doses of ATP-MGCL2 can be markedly ameliorated by atropine. Infusion of ATP-MGCL2 did not adversely affect hepatic or renal function, myocardium or blood chemistry shortly after infusion or even after a prolonged period of time. In conscious rats and primates bolus infusion of the entire efficacious dose of ATP-MGCL2 transiently decreased mean blood pressure but there were no long-term side effects and there were no mortalities. Results also indicate that infusion of ATP-MGCL2 in dogs, even during hypotension increases coronary flow and cardiac output while decreasing myocardial oxygen consumption. We evaluated the safety of ATP-MgCL2 administration in six patients with coronary artery disease. ATP-MgCL2 shows favorable characteristics for potential application in patients with coronary artery disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 31, 1986
- Accession Number
- ADA187076
Entities
People
- Arthur E. Baue
- Irshad Chaudry
Organizations
- Yale University